Mnemosyne Pharmaceuticals Garners $5,400,000 Series A Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=218e4cfe-e65c-4289-aff4-d76db40f316f&Preview=1
Date
2/17/2012
Company Name
Mnemosyne Pharmaceuticals
Mailing Address
3 Davol Square Providence, RI 02903
Company Description
The company is a Providence-based drug discovery venture aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders.
Website
http://www.mnemosynepharma.com
Transaction Type
Venture Equity
Transaction Amount
$5,400,000
Transaction Round
Series A
Proceeds Purposes
The company said that it will use the new funds in support of its drug discovery programs, including the identification of lead product candidates for treatment of schizophrenia and other neuropsychiatric disorders.
M&A Terms
Venture Investor
Access BridgeGap Ventures
Venture Investor
Slater Technology Fund